Wilson's Disease Drugs Market Report 2026

The wilson's disease drugs market size has grown strongly in recent years. It will grow from $0.66 billion in 2025 to $0.7 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to limited treatment options for wilson's disease, reliance on hospital-based care, lack of awareness about rare genetic disorders, growing research in chelation therapy, increasing demand for symptomatic management.

The wilson's disease drugs market size is expected to see strong growth in the next few years. It will grow to $0.9 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to development of novel chelating agents and experimental drugs, expansion of homecare services for chronic management, rising liver transplantation procedures, increasing adoption of oral and intravenous therapies, growth of specialty clinics and online pharmacy channels. Major trends in the forecast period include growing adoption of chelating agents for copper removal, rising preference for zinc-based therapies, increasing liver transplant procedures for advanced cases, expansion of symptomatic treatments for neurological manifestations, rising homecare and specialty clinic management.

The rising incidence of genetic disorders is anticipated to drive the growth of the Wilson’s disease drugs market in the coming years. Genetic disorders are conditions caused by abnormalities in an individual’s DNA, including mutations, deletions, or chromosomal alterations. The increase in genetic disorders is largely attributed to higher parental age, which elevates the likelihood of inheritable mutations being transmitted to offspring. Wilson’s disease drugs address this genetic condition by reducing toxic copper accumulation resulting from mutations in the ATP7B gene. These therapies work by promoting copper excretion or inhibiting its absorption, thereby safeguarding critical organs such as the liver and brain. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) during 2023-2024, an increase from 2,681 patients in 2022-2023. Therefore, the growing incidence of genetic disorders is contributing to the expansion of the Wilson’s disease drugs market.

Major companies operating in the Wilson’s disease drug market are concentrating on the development of advanced therapies, such as trientine tetrahydrochloride (TETA-4HCl)-based formulations, to improve treatment outcomes and enhance patient convenience in managing rare diseases. A trientine tetrahydrochloride (TETA-4HCl)-based formulation is an advanced oral copper-chelating therapy specifically designed to help maintain copper balance in adult patients with stable Wilson disease. For instance, in April 2023, Orphalan SA, a France-based orphan drug development and commercialization company, introduced Cuvrior. The drug received approval from the Food and Drug Administration (FDA) and was granted Orphan Drug Exclusivity. Cuvrior is a novel trientine tetrahydrochloride (TETA-4HCl) therapy intended for adults with stable Wilson disease who have already been decoppered and are tolerant to penicillamine. It offers a room-temperature-stable oral treatment that provides greater dosing flexibility and convenience compared to earlier therapies.

In January 2025, Eton Pharmaceuticals, a US-based pharmaceutical company, acquired Galzin from Teva Pharmaceuticals USA for an undisclosed sum. This acquisition is intended to reinforce Eton Pharmaceuticals’ focus on rare disease treatments by adding an FDA-approved therapy for the ultra-rare metabolic disorder Wilson disease to its portfolio. Teva Pharmaceuticals USA, Inc. is a US-based pharmaceutical company that produces Wilson’s disease drugs.

Major companies operating in the wilson's disease drugs market are Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Taj Pharmaceutical Limited, Biophore Pharma Inc., Orphalan SA, Nobelpharma Co. Ltd., Eton Pharmaceuticals Inc., LogicBio Therapeutics Inc., DepYmed Inc., Vivet Therapeutics SAS, Innorna, Apotex Inc., Hikma Pharmaceuticals PLC, Zydus Lifesciences Ltd., Cipla Ltd., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Strides Pharma Science Ltd., Wockhardt Ltd., Accord Healthcare Ltd., Mallinckrodt Pharmaceuticals, Meda AB, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Laurus Labs Ltd., MSN Laboratories Pvt. Ltd.

North America was the largest region in the wilson's disease drugs market in 2025. The regions covered in the wilson's disease drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the wilson's disease drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the wilson’s disease drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and specialized chelating agents, particularly impacting oral and intravenous formulations. Segments such as chelating agents and zinc therapies are most affected, with regions including Asia-Pacific countries like India and China facing significant import duties. This has resulted in higher treatment costs and supply chain adjustments. On the positive side, tariffs encourage domestic production, promote local manufacturing capabilities, and may stimulate investment in research and development of alternative therapies.

The wilson's disease drugs market research report is one of a series of new reports that provides wilson's disease drugs market statistics, including wilson's disease drugs industry global market size, regional shares, competitors with a wilson's disease drugs market share, detailed wilson's disease drugs market segments, market trends and opportunities, and any further data you may need to thrive in the wilson's disease drugs industry. This wilson's disease drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Wilson’s disease drugs are medications used to treat a rare genetic disorder that causes excessive accumulation of copper, primarily in the liver and brain. These drugs act by either promoting the removal of copper from the body or preventing its absorption. Their main objective is to prevent or reverse organ damage, particularly to the liver and the nervous system.

The main types of Wilson’s disease drugs include chelating agents, zinc therapy, liver transplants, and symptomatic treatments. Chelating agents manage Wilson’s disease by binding excess copper and facilitating its excretion through urine, thereby rapidly lowering toxic copper levels. These treatments are administered through various routes, such as oral, intravenous, and subcutaneous, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used by a range of end users, including hospitals, home care settings, specialty clinics, and others.

The wilson's disease drugs market consists of sales of zinc salts, penicillamine, and trientine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.